Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 25, 2026, 8:32 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Intranasal insulin Clear all
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Efficacy Study of Intranasal Insulin to Treat Tobacco Abstinence Syndrome

NCT01781234
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2016
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Dose-Dependent Effect of Intranasal Insulin in Humans Using Functional Magnetic Resonance Imaging (fMRI)

NCT06144255
View directory record Official record
Conditions
Healthy
Interventions
Intranasal insulin
Drug
Lead sponsor
Florian Schmitzberger
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Ann Arbor, Michigan
Source: ClinicalTrials.gov public record
Updated Mar 20, 2024 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Safety and Efficacy of Combining Intranasal Insulin & Acute Exercise

NCT04292535
View directory record Official record
Conditions
Insulin, Exercise
Interventions
Placebo into the intranasal mucosa, 20 IU NovoLog Insulin aspart into the intranasal mucosa, 40 IU NovoLog Insulin aspart into the intranasal mucosa, 60 IU NovoLog Insulin aspart into the intranasal mucosa, 80 IU NovoLog Insulin aspart into the intranasal mucosa, 100 IU NovoLog Insulin aspart into the intranasal mucosa, 120 IU NovoLog Insulin aspart into the intranasal mucosa
Drug
Lead sponsor
Michigan State University
Other
Eligibility
18 Years and older
Enrollment
116 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
East Lansing, Michigan
Source: ClinicalTrials.gov public record
Updated Jun 20, 2021 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2Phase 3 Interventional Results available

The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)

NCT01767909
View directory record Official record
Conditions
Amnestic Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Insulin (Humulin® R U-100), Placebo
Drug
Lead sponsor
University of Southern California
Other
Eligibility
55 Years to 85 Years
Enrollment
240 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
25
States / cities
Phoenix, Arizona • Irvine, California • New Haven, Connecticut + 18 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2024 · Synced Sep 25, 2026, 8:32 PM EDT
Recruiting Phase 1Phase 2 Interventional

Intranasal Insulin for Treatment of Alcohol Use Disorder

NCT05988632
View directory record Official record
Conditions
Alcohol Use Disorder
Interventions
Regular Human Insulin then Placebo, Placebo then Regular Human Insulin
Drug
Lead sponsor
Brown University
Other
Eligibility
21 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 4, 2025 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Results available

Effects of Nasulin Versus Placebo on Blood Glucose Control in Patient Volunteers With Type 2 Diabetes Mellitus

NCT00850096
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Placebo for Nasulin, Nasulin
Other · Drug
Lead sponsor
CPEX Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
94 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
21
States / cities
Chandler, Arizona • Escondido, California • La Jolla, California + 17 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2013 · Synced Sep 25, 2026, 8:32 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Intranasal Insulin for the Treatment of HAND

NCT03081117
View directory record Official record
Conditions
HIV Dementia, HIV-Associated Cognitive Motor Complex
Interventions
Insulin, intranasal, Placebo, intranasal
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 69 Years
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 6, 2021 · Synced Sep 25, 2026, 8:32 PM EDT
Recruiting Phase 2Phase 3 Interventional

Exercise and Intranasal Insulin in Type 2 Diabetes

NCT07675499
View directory record Official record
Conditions
Type 2 Diabetes, Insulin Sensitivity/Resistance, Cognition, Brain Blood Flow
Interventions
Intranasal Insulin, Intranasal Placebo, High Intensity Exercise
Drug · Behavioral
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
55 Years to 80 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
4
States / cities
New Brunswick, New Jersey • Piscataway, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 29, 2026 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Effect of Nasal Insulin on Postprandial Glycemic Control in Type 2 Diabetic Patients

NCT00624767
View directory record Official record
Conditions
Diabetes Mellitus
Interventions
Insulin (recombinant human insulin), NovoLog
Drug
Lead sponsor
Nastech Pharmaceutical Company, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
1
States / cities
San Antonio, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2008 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Effects of Intranasal Insulin on Neuroimaging Markers and Cognition in Patients With Psychotic Disorders

NCT03943537
View directory record Official record
Conditions
Psychosis, Schizophrenia, Schizo Affective Disorder, Bipolar I Disorder
Interventions
Intranasal Insulin
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 40 Years
Enrollment
87 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2024
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Sep 2, 2026 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Intranasal Insulin for Improving Cognitive Function in Multiple Sclerosis

NCT02988401
View directory record Official record
Conditions
Multiple Sclerosis, Relapsing-Remitting, Multiple Sclerosis, Secondary Progressive, Multiple Sclerosis, Primary Progressive
Interventions
Insulin, Placebo (Sterile diluent)
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 70 Years
Enrollment
105 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 9, 2023 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional

SNIFF 120: Study of Nasal Insulin to Fight Forgetfulness (120 Days)

NCT00438568
View directory record Official record
Conditions
Mild Cognitive Impairment, Alzheimer's Disease
Interventions
Regular Insulin, Placebo
Drug
Lead sponsor
University of Washington
Other
Eligibility
55 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 13, 2012 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Memory Aid by Intranasal Insulin in Diabetes (MemAID)

NCT02415556
View directory record Official record
Conditions
Type 2 Diabetes Mellitus
Interventions
Regular Human Insulin, Placebo
Drug
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
50 Years to 85 Years
Enrollment
289 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2020
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 18, 2022 · Synced Sep 25, 2026, 8:32 PM EDT
Suspended Early Phase 1 Interventional Accepts healthy volunteers

Impact of Intranasal Insulin on Sympathetic Activity and Cerebral Vasodilation

NCT05153395
View directory record Official record
Conditions
Healthy, Vasodilation, Insulin Resistance, Autonomic Dysfunction, Obesity
Interventions
Carbon dioxide breathing, Neurovascular Coupling, Human insulin
Other · Drug
Lead sponsor
University of Missouri-Columbia
Other
Eligibility
18 Years to 45 Years
Enrollment
65 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2027
U.S. locations
1
States / cities
Columbia, Missouri
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

SNIFF Multi-Device Study 2

NCT04199767
View directory record Official record
Conditions
Mild Cognitive Impairment, Cognitive Impairment
Interventions
20 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company), 40 IU Humulin® R U-100 (NDC: 0002-8215, Eli Lilly & Company)
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
55 Years to 85 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 1, 2026 · Synced Sep 25, 2026, 8:32 PM EDT
Not listed Phase 2 Interventional

Intranasal Insulin: A Novel Treatment for Gulf War Multisymptom Illness

NCT01802944
View directory record Official record
Conditions
Chronic Multisymptom Illness in Gulf War Veterans
Interventions
Intranasal Insulin, Placebos
Drug
Lead sponsor
Bronx Veterans Medical Research Foundation, Inc
Other
Eligibility
40 Years to 89 Years
Enrollment
114 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
2
States / cities
Boston, Massachusetts • The Bronx, New York
Source: ClinicalTrials.gov public record
Updated Oct 5, 2017 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Effect of Intranasal Insulin on LH Concentrations in Man

NCT02154477
View directory record Official record
Conditions
Hypogonadotropic Hypogonadism
Interventions
intranasal insulin, placebo (intranasal saline)
Drug
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
18 Years to 75 Years · Male only
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
1
States / cities
Odessa, Texas
Source: ClinicalTrials.gov public record
Updated Aug 12, 2019 · Synced Sep 25, 2026, 8:32 PM EDT
Recruiting Phase 1 Interventional

Safety and Feasibility of Intranasal Insulin in Patients With Spinal Cord Injury

NCT07384052
View directory record Official record
Conditions
Spinal Cord Injury
Interventions
Regular Insulin, 0.9 % Normal Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
18 Years to 84 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 14, 2026 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin for Posttraumatic Stress Disorder

NCT04044534
View directory record Official record
Conditions
PTSD
Interventions
Intranasal insulin, Placebo
Drug
Lead sponsor
VA Connecticut Healthcare System
Federal
Eligibility
21 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
West Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 12, 2026 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Intranasal Insulin for Weight Management During Smoking Cessation

NCT02028871
View directory record Official record
Conditions
Tobacco Abstinence Syndrome
Interventions
Intranasal Insulin, Placebo
Drug
Lead sponsor
Ajna Hamidovic
Other
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2016
U.S. locations
2
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Dec 9, 2018 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional Results available

Intranasal Insulin and Post-stroke Cognition: A Pilot Study

NCT02810392
View directory record Official record
Conditions
Stroke
Interventions
Intranasal Insulin, Intranasal saline
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
40 Years to 89 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Sep 25, 2026, 8:32 PM EDT
Withdrawn Phase 1 Interventional Accepts healthy volunteers

Measurement of Insulin Levels in the Cerebrospinal Fluid of Healthy Adults After a Single Intranasal Dose - Middle Age

NCT06434038
View directory record Official record
Conditions
Healthy
Interventions
Low Dose Regular insulin, High Dose Regular insulin, 0.9% Saline
Drug · Other
Lead sponsor
HealthPartners Institute
Other
Eligibility
36 Years to 55 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Saint Paul, Minnesota
Source: ClinicalTrials.gov public record
Updated Nov 24, 2025 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 2 Interventional

Study of Nasal Insulin to Fight Forgetfulness - Long-acting Insulin Detemir - 21 Days

NCT01547169
View directory record Official record
Conditions
Alzheimer's Disease, Mild Cognitive Impairment
Interventions
Placebo Comparator, insulin detemir
Drug
Lead sponsor
University of Washington
Other
Eligibility
50 Years to 89 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Dec 17, 2012 · Synced Sep 25, 2026, 8:32 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Intake and Intra-Nasal Insulin for African American Adults (FIINAAL)

NCT04739371
View directory record Official record
Conditions
Insulin
Interventions
Insulin, Regular, Human, Placebo
Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
45 Years to 65 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 25, 2026, 8:32 PM EDT